In December 2021, a kit for detecting deficient mismatch-repair (MMR) function that consists of 4 IHC test kits, each of which detects an MMR protein expressed in tumor tissue (MLH1, MSH2, MSH6, and PMS2), was approved as an in vitro diagnostic in Japan. This evidence concerns the gene MSH2 and neoplasm.